Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant.
NA Vice President
Peggy Robinson is leading relationships with US key opinion leaders and responsible for US sales and corporate deals with major pharmaceutical and medtech companies. Prior to joining ANGLE, Peggy was the principal of BioMark Consulting, LLC, a boutique consulting firm focused on business strategies, marketing, strategic alliances, KOL and product development of new technologies, with an emphasis on cancer diagnostics, chronic diseases and companion diagnostics.
Chief Technology Officer
Jay joined ANGLE in 2017 with over thirty years of experience in Life Science / Medical product development, covering multi-partner collaborations, technology acquisition, IP management, project management, quality systems (ISO9001, ISO13485), clinical trials, business development and successful technology commercialisation in international markets.
US Chief Technology Officer Microfluidics
George E. Hvichia, PhD, inventor of the Parsortix technology, and Vice President of Research was trained in Bioengineering and is an expert in Microfluidics and Biochips. He has developed microdevices for industry and in academic settings.
Chief Financial Officer
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
Business Development Director
Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership. Michael joined ANGLE six years ago to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers.
Director of Operations & Regulatory Affairs
Martin is the Head of Manufacturing and Regulatory at Parsortix, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and specialises in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.
Clinical Studies Director
Craig Miller joined ANGLE in March of 2016 as the Clinical Studies Director, where he is responsible for driving the clinical development activities of ANGLE. He has over 20 years of experience in the RUO and IVD diagnostics industry, including clinical trial management, clinical data management, biostatistics, regulatory submissions, and manuscript writing and editing (Craig is a co-author on over 80 peer-reviewed publications in the field of oncology and diagnostics).
U.S. Vice President Sales
Brad Spitz joined ANGLE in 2016 and has responsibility for sales strategies and tactics in North America. Brad is a highly accomplished life sciences executive who has diverse experience spanning the biotech, pharmaceutical, molecular diagnostics, and oncology healthcare sectors.
Vice President; CEO ANGLE Biosciences, Inc.